USPTO serial 88056022
Serial No. 88056022
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 25, 2019
- Examiner
- RICHARDS, LESLIE
- Law office
- Historical data usage
What this means
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
Need help with Serial No. 88056022?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karl S. Kronenberger
Karl S. Kronenberger Kronenberger Rosenfeld LLP548 Market St.#85399San Francisco, CA 94104Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for chelation treatments; Medicinal preparations for promoting men's health, namely, treating erectile dysfunction, andropause, and male fertility, and performing testosterone replacement therapies; Medicinal preparations for promoting women's health, namely, treating menopause and female fertility; Medicinal preparations for hormone replacement therapy; Medicinal preparations for weight management; Medicinal preparations for prolotherapy treatments to treat inflammation, localized pain, generalized pain, and ligament laxity; Medicinal preparations for promoting animal health in the nature of infections, pain, inflammation, cancer, autoimmune disease, and ocular disease; Medicinal preparations for oncology treatments; Medicinal preparations for pain management; Prescription medicines, namely, intravenous pharmaceutical preparations for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Prescription medicines, namely, topical medications for the treatment of cancer, weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain; Prescription medicines, namely, custom compounded medications for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Prescription medicines, namely, custom compounded medications for intravenous administration for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Prescription medicines, namely, custom compounded medications for topical administration for the treatment of cancer, weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain; Prescription medicines, namely, custom compounded medications for nasal administration for weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, allergies, and neurotransmitter deficiencies; Medicinal preparations for the body to be applied in the form of intravenous fluids for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Medicinal preparations for the body to be applied in the form of topical ointments for the treatment of cancer, weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain; Medicinal preparations for the body to be applied in the form of nasal sprays for weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, allergies, and neurotransmitter deficiencies; Custom compounded medicinal preparations for the body to be applied in the form of intravenous fluids for the treatment of cancer, cardiovascular disease, weight loss, diabetes, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain, environmental toxicities, and heavy metal toxicities; Custom compounded medicinal preparations for the body to be applied in the form of topical ointments for the treatment of cancer, weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, pain; Custom compounded medicinal preparations for the body to be applied in the form of nasal sprays for weight loss, hormone replacement, nutritional deficiencies, infectious disease, autoimmune disease, fatigue, inflammation, allergies, and neurotransmitter deficiencies | ACTIVE | Nov 26, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 7, 2025 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jan 7, 2025 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Dec 16, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 12, 2024 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jun 25, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 1, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 1, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 1, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 12, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 12, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 12, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 10, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 25, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 24, 2019 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| May 23, 2019 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| May 22, 2019 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| May 21, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 7, 2019 | IUAF | USE AMENDMENT FILED | — |
| May 7, 2019 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Mar 12, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 15, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 15, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 26, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 6, 2018 | ALIE | ASSIGNED TO LIE | — |
| Nov 16, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 16, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 16, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 16, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 16, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 14, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 4, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 3, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 31, 2018 | NWAP | NEW APPLICATION ENTERED | — |